Check-Cap (NASDAQ:MBAI) Now Covered by Northland Securities

Investment analysts at Northland Securities initiated coverage on shares of Check-Cap (NASDAQ:MBAI) in a research report issued on Monday, Briefing.com reports. The brokerage set an “outperform” rating and a $10.00 price target on the stock. Northland Securities’ price target would indicate a potential upside of 136.13% from the company’s current price.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Check-Cap in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Check-Cap Trading Down 7.7%

Shares of NASDAQ:MBAI traded down $0.35 during trading on Monday, hitting $4.24. 8,672 shares of the company’s stock traded hands, compared to its average volume of 131,836. The company has a market cap of $5.84 million, a price-to-earnings ratio of -0.30 and a beta of 0.67. The company has a 50-day moving average price of $7.23 and a 200-day moving average price of $9.55. Check-Cap has a 52 week low of $3.88 and a 52 week high of $27.44.

About Check-Cap

Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.

The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body.